Canada: Drug Price Clarifications And Complexities: Draft PMPRB Guidelines Published For Consultation

Canada's Patented Medicines Prices Review Board (PMPRB) has published draft guidelines for stakeholder consultation.

What you need to know

  • The PMPRB is seeking feedback on the guidelines until January 20, 2020. All written submissions will be published. It is anticipated that a final version of the guidelines will be published shortly thereafter.
  • The guidelines implement the recently amended Patented Medicine Regulations (regulations), which come into force on July 1, 2020, and describe the pricing tests that will be used by PMPRB staff to assess if a patented medicine is being priced excessively.
  • The guidelines, once finalized, will not be law but describe how price ceilings will typically be set by PMPRB staff.
  • The application of various provisions of the guidelines will differ depending on whether a medicine is classified by PMPRB as Category I (high risk of excessive pricing) versus Category II (lower risk of excessive pricing), and whether the medicine is grandfathered under the previous version of the regulations.
  • The draft guidelines also provide guidance to patentees on how to comply with the new filing requirements in the regulations.

Key aspects of the guidelines


In accordance with the regulations, patented medicines which received a drug identification number (DIN) prior to August 21, 2019 (the date of publication of the regulations) are considered "grandfathered" medicines and are not subject to new regulatory factors and associated information reporting requirements that apply to medicines that receive a DIN after August 21, 2019.1 Patented medicines sold in Canada under the special access program (SAP) prior to August 21, 2019 will not be grandfathered because SAP medicines are not assigned a DIN. In addition, line extensions of existing medicines that are assigned a DIN after August 21, 2019 are not grandfathered even though the patented medicines on which the line extensions are based and existing before August 21, 2019 would be grandfathered.

As discussed in our previous bulletin, all DINs will be subject to international price tests based on a basket of countries called the PMPRB11. The PMPRB11 does not include the United States or Switzerland, which were used as international pricing comparators under the old regime. So, all patented medicines, whether Category I or II, or whether grandfathered or non-grandfathered, will be assessed based on the PMPRB11, which will likely require decreases in Canadian prices for many products.

Category I vs. Category II

Category I medicines are subject to price tests that are not applicable to Category II products. A Category I medicine is defined by the guidelines as having: (a) a 12-month treatment cost of greater than 50% of GDP per capita (based on dosing set out in the product monograph),2 or (b) estimated or actual annual revenues that exceed $25M. The latter threshold is subject to adjustments at least every five years. The federal government expects the majority of patented medicines to fall into Category II.

For Category I medicines, patentees will be required to file cost utility analyses conducted by the Canadian Agency for Drugs and Technologies in Health (CADTH) and l'Institut national d'excellence en santé et services sociaux (INESSS). The guidelines state that the PMPRB will not duplicate the pharmacoeconomic analysis undertaken by CADTH and INESSS. Category I medicines would then be subject to a comprehensive review under the new factors to determine whether their price is potentially excessive.

Price review process

After determining whether a medicine has been grandfathered, PMPRB staff would perform price review in accordance with the following process:

  1. When a new patented medicine is launched in Canada, an interim maximum list price (iMLP) will be established as the median international list price (MIP) within the PMPRB11 where the patentee is selling the same medicine. The Canadian list price must not be greater than the iMLP.
  2. The iMLP is recalculated annually and will apply until the earlier of: (a) three years from the date that the medicine was launched, or (b) the date upon which the patentee has filed price information for at least five of the PMPRB11 countries. At this time, a maximum list price (MLP) will be set and will be the lower of the MIP or the median domestic Therapeutic Class Comparison (dTCC). The MLP will not be set lower than the lowest international price (LIP). In sum, the maximum price for the medicine will only be based on comparators sold in Canada when the price of the Canadian comparators is lower than the median international price of the medicine and will be subject to a price floor set by the lowest price within the PMPRB11.
    • Where list prices vary from province to province, or where there are multiple reported list prices internationally, PMPRB will use the lowest available price in its calculations.
    • Where the MLP is based on therapeutic comparators, there may be some room for negotiations with PMPRB staff on the appropriate comparator.
  3. For Category I medicines, a maximum rebated price (MRP) is also established, based upon the pharmacoeconomic value and market size for the medicine. The MRP reflects "non-transparent" rebates and discounts that are provided by the manufacturer, as opposed to the MLP which is based upon the public list price. The MRP has regard to the marginal cost of a quality-adjusted life year (QALY) within Canada's health system (i.e., the point at which spending on a new health technology for one set of patients will result in the loss of one QALY for another set of patients). The MRP will then be the price at which the patented medicine's cost per QALY would be equivalent to the threshold of C$60,000 per QALY, subject to additional adjustment due to market size (e.g., if annual revenues at the MRP price would exceed $25M). Category I medicines that treat conditions with very low prevalence in Canada, would be allowed a 50% percent increase in the MRP, if annual revenues fall within a $12.5M average annual affordability threshold.3
  4. Category II medicines, regarded as medicines at lower risk of being excessively priced, would face relatively less oversight. Pricing compliance for Category II medicines would be assessed solely based on MLP (not MRP).
  5. Under the guidelines, patentees would have flexibility to vary their pricing from year to year, provided it remains below the MLP and MRP, as applicable.
  6. Grandfathered medicines are subject to an MLP test but not the MRP test. The MLP for grandfathered medicines is the lower of the MIP for the PMPRB11 countries for which sales data has been reported, and the maximum ceiling price as calculated under the previous version of the guidelines (the federal government comments that the MIP is considered to be consistent with Canada's responsibility to pay its fair share for global pharmaceutical innovation). The MLP may also be adjusted by CPI in certain circumstance

    Because of current limitations in data capture and reporting on volume per indication, the PMPRB considered and rejected indication-specific pricing. The draft guidelines adopt the approach of a single price ceiling across multiple indications.


The guidelines contemplate ongoing reassessments for non-grandfathered patented medicines, meaning patented medicines could move from Category II to Category I during their lifecycle, and the price ceilings could be revised in various situations. For example, approval of a new indication, an increase in sales over the estimated threshold or an update to a cost-utility analysis can trigger a reassessment. In addition, there is a reassessment procedure for patented medicines that may warrant a higher or lower ceiling because of changes in market conditions.

For all patented medicines, if the MLP is set by the MIP and over time, the MIP is lower than the MLP by more than 10%, the MLP will be reset. Conversely, if the MIP exceeds the MLP by more than 10%, the MLP may be adjusted based on actual lagged CPI, as long as the MLP does not exceed the MIP.

When the price ceilings are altered, patentees will be given notice by PMPRB staff and will be required to adjust pricing by the end of the subsequent reporting period to avoid an investigation.


The process for investigations and their outcomes remains substantially similar under the guidelines. As under the old regime, an investigation is triggered when the price of any DIN of a patented medicine appears to be more than 5% above the price ceiling, the cumulated potential excess revenue exceeds $50,000 or a complaint about the patented medicine is received by PMPRB.

If the PMPRB staff determines that the price of the patented medicine is excessive, the patentee will be asked to enter into a voluntary compliance undertaking (VCU) whereby the price of the medicine is reduced and excess revenues are offset by a payment (typically to the federal government). If a VCU is not reached, the matter may proceed to a hearing. The guidelines state that they are not binding on staff, hearing panels or patentees.

The guidelines remind patentees that Canadian patents that are not eligible for listing on Canada's Patent Register under the Patented Medicines (Notice of Compliance) Regulations may nonetheless "pertain to" medicines sold in Canada and trigger PMPRB jurisdiction.


The guidelines expressly provide that information or documents provided to the PMPRB (e.g., revenues, average price or net revenues and associated discounts and rebates) or in any proceeding relating to excessive prices is privileged and cannot be disclosed to the public without authorization of the patentee, unless such information has already been disclosed or is within other exceptions outlined in the Patent Act.

What's next

While some updates to the guidelines may be made based on stakeholder feedback during the consultation phase, it is expected that the new approach to price review will not be materially altered in the final version.

As noted above, the regulations come into force on July 1, 2020, and so it is expected that the final guidelines will be published in spring of 2020. All patentees will be subject to the requirements of the final guidelines.


1. For further information, please see our bulletin: " Drug price cooling in Canada's election year: Release of final PMPRB regulations".

2. Canada's GDP per capita (2018) is reported by the Government of Canada to be C$59,879 (approximately US$45,000). Learn more here.

3. Guidelines set out a threshold for a rare disease or disorder as any disease that is found in less than 1 in 2,000 Canadians.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions